Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Aquarius Biotechnologies, Inc. (Details Textual)

v3.4.0.3
Acquisition of Aquarius Biotechnologies, Inc. (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended
Jan. 29, 2015
Mar. 31, 2016
Dec. 31, 2015
Business Acquisition [Line Items]      
Percentage Of Approval Shareholders 100.00%    
Indefinite-Lived Intangible Assets (Excluding Goodwill)   $ 3,017,377 $ 3,017,377
Goodwill, Subsequent Recognition of Deferred Tax Asset   $ 48,000  
Additional Paid-in Capital [Member]      
Business Acquisition [Line Items]      
Business Combination, Contingent Consideration, Liability     $ 753,346
Aquarius Biotechnologies, Inc. [Member]      
Business Acquisition [Line Items]      
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 4,608,020    
Business Acquisition, Share Price $ 0.46    
Business Combination, Contingent Consideration, Upon Achieving Certain Future Clinical Milestone, Number of Shares Issuable 5,000,000    
Business Combination, Contingent Consideration, Upon Achieving Certain Future Regulatory Milestone, Number of Shares Issuable 3,000,000    
Milestone Consideration Description (i) 1,500,000 shares issuable upon the dosing of the first patient in a phase III trial sponsored by us for a product utilizing Aquarius’ proprietary cochleate delivery technology and (ii) 1,500,000 shares issuable upon FDA approval of the first NDA submitted by us for a product utilizing Aquarius’ proprietary cochleate delivery technology. As discussed in footnote (15) the Company ultimately concluded that the contingent share issuance represented equity settled contingent consideration and as such have reclassified the amounts to equity as of December 31, 2015.    
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net $ 2,873,035